Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.
The meeting was attended by 166 shareholders, representing a total of 97'748'740 shares, or 43.28% of the total outstanding shares.
Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update.
Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented:'On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.'
The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote.
The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward.
The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024.
The shareholders approved the amendments to the Articles of Association regarding share capital.
The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius.
Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026.
BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026.
Deloitte AG, Basel, was re-elected as the company's statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026).
Notes to the editor
About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients.
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.
Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
Press Release PDF
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
‘Calming Box' sparks controversy in Aurora
AURORA, Mo. — Parents in Aurora are outraged after photos of a 'calming box' inside one of the school buildings surfaced online. 'When we were first starting [our child] with getting help in the school and the special needs room for his ADHD, we were told there was a sensory room where there were like weighted blankets and puppets and squished balls and stuff like that, but nothing even remotely close to a calming box,' said parents Mikayla Thomas and Tiya McKinney. Photos show a box made of wood, with padding on the walls and the door, which does not appear to have any latch of any kind. For Thomas and McKinney, they weren't aware of the box, and say it's a source of trauma. 'I turned it around to [my son], and he just froze completely and started crying. Whenever I asked him was like, Have you ever seen this? Do you know what this is? He couldn't even talk. He couldn't even talk, and he just started crying,' McKinney said. 'Seeing your nine year old break down like that, it hurts for one, and it makes you feel like crap because you had no idea that this was going on and you couldn't protect your kid,' Thomas said. Ozarks First reached out to the Aurora School District. Dr. Ben Yocom, the district's superintendent, gave this statement: 'The Aurora R-VIII School District is aware of a recent social media post by an individual using the pseudonym 'Splater Butt' concerning a calming space located within one of the District's behavioral classrooms. The post includes a photograph of a calming space and refers to it as a 'box.' To clarify, the calming space (sometimes referred to as the calming box) does not include a top (roof) but rather is completely open. Students in the calming space can stand straight up, stretch out their arms completely, safely navigate the padded walls in the calming space, and are completely visible and accessible while inside the calming space. There is no locking mechanism on the door of the calming space and no student is left alone or unsupervised in the space. The calming space is an established component of the classroom environment designed to support the behavioral and emotional regulation of students. The District remains committed to ensuring safe, lawful, and developmentally appropriate support for all students. As such, the calming space is utilized in two capacities: (1) voluntarily by students as a self-regulation strategy; and (2) as part of a restrictive behavioral intervention consistent with Missouri Revised Statutes § 160.263 and Board of Education Policy JGGA: Seclusion and Restraint. As transparency and student safety remain priorities in the District's behavioral support practices, each school year, the District provides parents and guardians with information regarding the calming space, including the opportunity to view the area in person. Parents who have questions, concerns, or complaints regarding the calming space are encouraged to contact Superintendent Dr. Ben Yocom at 417-678-3373.' Thomas and McKinney say they don't care if the box or space has a roof. 'Regardless of if there's an open top, it really doesn't matter. There are a hundred different ways that I could explain that a child could get hurt in that thing, with or without a top, with or without a door, with or without a teacher present in there. It's just not safe. It's not okay. It's not safe,' Thomas said. Thomas and McKinney say until changes are made, their kids won't be part of the Aurora School District. 'I feel like the only way that we would feel comfortable putting our kids back in this school district is if we have a 100% certainty that this is being removed,' McKinney said. 'It's not okay. The way they're using it is completely wrong.' The two say contacting parents is the best way to maintain a level of trust between parents and school staff. 'Call. Let us take care of our child. If you can't ultimately calm them down, give us a chance. We've raised them. We've been with them their whole life. Every single day. We are with them. You're only with them four days out of the week. Don't traumatize them,' Thomas said. Thomas says she's meeting with an attorney on Wednesday to discuss potential litigation and encourages any parents who have endured a similar situation with the district, specifically regarding the calming box/space, to reach out over social media through her fiancé's Facebook account. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities. 'As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee,' said Lynn Seely, MD, Lyell's President and Chief Executive Officer. 'Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.' 'The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314,' said Rick Klausner, MD, Chairman of the Lyell Board of Directors. 'I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.' Mark J. Bachleda, PharmD, MBA appointed independent member of the Board of Directors Dr. Bachleda is currently the Chief Executive Officer and a member of the Board of Directors of Eyconis, Inc., a biopharmaceutical company focused on developing therapeutics for eye diseases. He has served in executive leadership roles at Amgen, Juno Therapeutics, and Bristol Myers Squibb (BMS), and, most recently, he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President & U.S. Business Unit Head of the CAR T-cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS. Prior to this, he was Vice President, Sales & Account Management at Juno when it was acquired by Celgene. His experience includes a 15-year career at Amgen in the U.S. and international roles of increasing responsibility up to Country President & General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc., and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his PharmD degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley. David Shook, MD appointed Chief Medical Officer Dr. Shook is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook was Chief Medical Officer and Head of Research and Development at Nkarta where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth and was Fellowship Director and a Faculty Member at St. Jude Children's Research Hospital. While at St. Jude, he conducted multiple first-in-human cell therapy trials, as well as research in the laboratory of Dario Campana, MD, PhD where he co-developed the membrane bound form of interleukin-15. He earned an MD from The Johns Hopkins University School of Medicine and a BS from Purdue University. Mark Meltz, JD appointed General Counsel and Corporate Secretary Mr. Meltz is an accomplished legal and business executive with more than two decades of experience leading and advising life sciences, technology and emerging growth companies. Prior to joining Lyell, Mr. Meltz was Chief Operating Officer and General Counsel of Kinnate Biopharma Inc., a clinical stage precision oncology company, through its sale to XOMA Corporation. Before Kinnate, he was Senior Vice President and General Counsel of Audentes Therapeutics through its sale to Astellas Pharma. Mr. Meltz also was previously Executive Vice President and Chief Business Development and Legal Officer at PaxVax through its sale to Emergent BioSolutions. Earlier in his career, Mr. Meltz was Associate General Counsel at Biogen and Head of Legal for North America at Novartis in its Vaccines & Diagnostics division. Mr. Meltz has supported multiple commercial launches at PaxVax, Biogen and Novartis. He earned a BA with Departmental Honors in Psychology from Yale University and a JD, Magna Cum Laude, from Boston College Law School. Jarrad Aguirre, MD, MBA appointed Senior Vice President, Medical Affairs Dr. Aguirre joined Lyell as Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an MD and an MBA from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a BS in Biology from Yale University. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of the Company's additions to its leadership team and Board of Directors, including the anticipated benefits of expanded strength of the Company's clinical and commercial capabilities; the continued clinical progress and anticipated commercial launch of the LYL314 trials; Lyell's anticipated progress, business plans, business strategy and clinical trials; Lyell's advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell's product candidates; and other statements that are not historical fact. These statements are based on Lyell's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the ability to retain the continued service of its key personnel; the complexity of manufacturing cellular therapies, which subjects Lyell to a multitude of manufacturing risks, any of which could substantially increase our costs, delay Lyell's programs or limit supply of Lyell's product candidates; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell's ability to initiate or progress clinical trials on the anticipated timelines, if at all; Lyell's limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell's product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell's product candidates; the significant uncertainty associated with Lyell's product candidates ever receiving any regulatory approvals; Lyell's ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell's strategic plans for its business and product candidates; the sufficiency of Lyell's capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading 'Risk Factors' in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in to access your portfolio
Yahoo
6 hours ago
- Yahoo
GRUPO SIMEC SAB DE CV ANNOUNCES THE PRESENTATION OF DOCUMENT 20F TO THE SEC
GUADALAJARA, Mexico, June 11, 2025 /PRNewswire/ -- Grupo Simec, S.A.B. de C.V. (NYSE-MKT: SIM) (the "Company") May 15, 2025 filed its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission at The Form 20-F is also available on the investor relations section of the Company's website at Shareholders may request a hard copy of the Form 20-F, including the Company's complete audited financial statements for the year ended December 31, 2024, free of charge, by contacting the Company's Finance coordinator, Mario Moreno Cortez, by email at mmoreno@ About Grupo Simec Grupo Simec is a diversified manufacturer, processor and distributor of SBQ steel and structural steel products with production and commercial operations in Mexico and Brazil, and limited commercial operations in the United States. Grupo Simec is also an important producer of structural and light structural steel products in Mexico in terms of sales volume. Grupo Simec's SBQ products are used across a broad range of highly engineered end-user applications, including axles, hubs and crankshafts for automobiles and light trucks, machine tools and off-highway. Contact: Mario Moreno CortezGrupo Simec, S.A.B. de Lázaro Cárdenas 60144440 Guadalajara, Jalisco, México+52 33 3770 6734 View original content: SOURCE Grupo Simec, S.A.B. de C.V.
